TECHNICAL MANUAL

Pharmacokinetic and pharmacodynamic characteristics
• ZACTRAN® (gamithromycin) is ≥95% bioavailable following subcutaneous (SC) injection. 4 *
• ZACTRAN is rapidly and extensively distributed throughout the lungs following SC injection. 3-5 *
• ZACTRAN reaches levels above MIC 90
for common bacterial BRD pathogens in lung tissue
within 30 minutes. 5 *
• ZACTRAN remains at high concentrations above MIC 90
in lung tissue and
bronchoalveolar lavage (BAL) cells for 10 days. 5 *
* Clinical relevance has not been determined.
Clinical study results
• In field trials, cattle treated with ZACTRAN showed a rapid response and significant
improvement in BRD clinical signs within 24 hours after treatment. 1
• In field trials, ZACTRAN provided 10-day treatment and control of BRD from a single dose. 1,2
Indications 3
ZACTRAN is indicated for the treatment of BRD associated with Mannheimia haemolytica,
Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle.
ZACTRAN is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle
at high risk of developing BRD associated with M. haemolytica and P. multocida.
IMPORTANT SAFETY INFORMATION: For use in cattle only. Do not treat cattle within 35 days
of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle
20 months of age or older, or in calves to be processed for veal. The effects of ZACTRAN on bovine
reproductive performance, pregnancy and lactation have not been determined.
3